Vital Care Express LogoVital Care Express
Oncology

A protein called TEX264 drags jammed PARP1 off a tumor's DNA, which is how aggressive cancers shrug off drugs that should kill them. Block it and the cancer becomes vulnerable again.

July 28, 2026
#Oncology#PARP Inhibitors#Cancer Research#DNA Repair#TEX264
A protein called TEX264 drags jammed PARP1 off a tumor's DNA, which is how aggressive cancers shrug off drugs that should kill them. Block it and the cancer becomes vulnerable again.

A drug that works, until it doesn’t

PARP inhibitors are one of oncology’s better tricks against ovarian and breast cancer. The problem is how often they wear off. Somewhere between 40% and 70% of patients treated with them eventually watch the cancer come back, adapted and unbothered by the drug that used to hold it down.

A study published in Nature Cell Biology in June 2026 figured out one of the escape routes, and it is oddly mechanical. The tumor has, in effect, a tow truck. It hooks onto the drug’s own trap and hauls it away. Find the tow truck, disable it, and the trap holds. The team named the culprit protein: TEX264.

How the drug is supposed to win

Cells rely on an enzyme called PARP1 to spot and patch small breaks in their DNA. PARP inhibitor drugs sabotage that repair crew in a clever way. Instead of just switching PARP1 off, the drug glues it onto the DNA strand, turning a repair worker into a roadblock.

For a tumor that is already bad at DNA repair, the kind with BRCA mutations, that roadblock is fatal. When the cell tries to copy its DNA, it slams into the stuck enzyme, the copying machinery stalls, and the DNA snaps into breaks the cell cannot fix. The cell dies. That is the whole strategy, and when it works it works well.

The tumor’s workaround

Aggressive tumors found a way to clear the roadblock. Researchers led by Gwendoline Hoslett, Professor Kristijan Ramadan, and PhD student Joanne Loh at Nanyang Technological University in Singapore, with international partners, traced it to a cleanup process called nucleophagy, the cell’s way of selectively taking out its own nuclear trash. MedicalXpress covered the work on 27 July 2026.

TEX264 is the key. It is the receptor that recognizes the trapped PARP1 and marks it for removal. When a PARP inhibitor locks PARP1 onto the DNA, TEX264’s binding to that enzyme jumps by 40%. It then teams up with a partner protein (p97, also called VCP) that physically wrenches the stuck enzyme off the strand, and hands it off to be dissolved inside the cell. Roadblock cleared, cell survives, drug defeated.

What happened when they cut the tow truck’s cable

Here is the part that turns a mechanism into a lead. When the researchers disabled TEX264, the trapped PARP1 had nowhere to go. It stayed jammed on the DNA and piled up. The amount of DNA-stuck PARP1 rose by about 70%, and markers of DNA damage climbed by 40% to 110% across different measures.

In plain terms: with the tow truck gone, the roadblocks accumulated, the cell could not copy its DNA, and cancer cells that had been resistant became killable again. That is the whole hope in one experiment.

Does it hold up in real patients?

The lab result needed a reality check, so the team looked at 700 people with triple-negative breast cancer in Sweden’s SCAN-B database (trial identifier NCT02306096). Triple-negative is one of the harder breast cancers to treat, lacking the three receptors most therapies aim at.

The pattern held. Patients whose tumors naturally made little TEX264 had a 28% higher 10-year survival rate than those with high levels. It fits the mechanism cleanly: a tumor with a weak tow truck cannot clear the damage, so it stays vulnerable, and more of those patients were alive a decade later.

The honest state of this

This is a genuine lead, and it is also early. Worth holding both thoughts at once.

The experiments that reversed resistance happened in cells in a dish, not in people. The survival finding came from looking backward at existing records, which shows TEX264 and outcome move together but cannot by itself prove that lowering TEX264 would save a given patient. And crucially, no human trial of the combination has been run.

The appealing part is that the tools to block TEX264’s pathway may already sit in the pharmacy. The authors flag chloroquine and hydroxychloroquine, both long approved for other uses, as candidates to pair with a PARP inhibitor. Repurposing an existing drug skips years of development. But the coverage did not report doses, side-effect profiles, or any trial start date, and the team says it is still looking for clinical partners and funding to test the idea in humans. Promising is the right word. Proven is not.

Sources:

Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.

Frequently Asked Questions

In plain terms, what does TEX264 do?

PARP inhibitor drugs work by jamming an enzyme called PARP1 onto the tumor's DNA so the cell cannot copy itself and dies. TEX264 is the tow truck that hauls the jammed enzyme away. When a tumor has plenty of TEX264, it clears the roadblock, survives, and the drug stops working.

How often do PARP inhibitors stop working?

Often. Between 40% and 70% of patients treated for ovarian and breast cancers eventually see their tumors become resistant. These drugs frequently work well at first and then lose their grip, which is the exact problem this research is trying to explain.

Did low TEX264 actually track with living longer?

Yes, in patient data. Among 700 people with triple-negative breast cancer in Sweden's SCAN-B database, those whose tumors made little TEX264 had a 28% higher 10-year survival rate than those with high levels. Less of the tow truck meant the drug's roadblock stayed in place.

Are there drugs that could block TEX264 today?

The researchers point to two that already exist, chloroquine and hydroxychloroquine, both approved for other conditions. That matters because it is faster to test an existing drug in a new combination than to invent one from scratch. But this is a proposal, not a proven treatment.

So is this ready for patients?

No, and it is important to be clear about that. The experiments that reversed resistance were done in cells in the lab, not in people. The survival link came from looking back at existing patient records, which shows a correlation, not proof. No human trial of the combination has been run, and the team says it is still seeking partners and funding to get there.

AI Assisted